HALOZYME THERAPEUTICS (HALO) Company Report

Halozyme Therapeutics, Inc. has completed its acquisition of Elektrofi, Inc., a biopharmaceutical company specializing in the Hypercon™ ultra-high concentration microparticle formulation technology.
The acquisition involved an upfront payment of $750 million and up to $150 million in contingent milestone payments, bringing the total consideration to up to $900 million.
Halozyme projects royalty revenues from this acquisition to begin as early as 2030, with potential development and commercial milestone payments of up to $275 million from Elektrofi's existing partner programs expected to enter clinical development by year-end 2026 or earlier.
The transaction is expected to be less than 5% dilutive to non-GAAP diluted EPS over the medium-term and will incur an incremental operating expense of approximately $55 million for full year 2026.

4 days ago

Press Release

Halozyme and Merus Announce Collaboration for ENHANZE® Technology

HALO

New Projects/Investments

Product Launch

Halozyme Therapeutics and Merus N.V. have entered into a global non-exclusive collaboration and license agreement.
Merus has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody.
Under the terms, Halozyme will receive an upfront payment, potential future milestone payments, and up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE® technology.

5 days ago

Press Release

HALOZYME THERAPEUTICS, INC. Details Terms for Convertible Notes

HALO

Debt Issuance

M&A

Convertible Preferred Issuance

Additional Interest will accrue on notes at a rate of 0.25% per annum for the first 90 days and 0.50% per annum thereafter if HALOZYME THERAPEUTICS, INC. fails to timely file required reports or if the notes are not "Freely Tradable".
The Conversion Rate of the notes is subject to adjustments for various corporate actions, including stock dividends, splits, combinations, and distributions of rights, options, or warrants.
In the event of a Make-Whole Fundamental Change, the Conversion Rate will be increased by Additional Shares based on the Stock Price and the Make-Whole Fundamental Change Effective Date.
A Fundamental Change is defined by events such as a change in beneficial ownership exceeding 50% of voting power, the sale of substantially all assets, liquidation, or delisting of common stock.

Nov 12, 2025, 10:17 PM

8-K

Halozyme: FDA Approves DARZALEX Faspro® for High-Risk Smoldering Multiple Myeloma

HALO

Product Launch

New Projects/Investments

Halozyme Therapeutics (HALO) announced that Johnson & Johnson received FDA approval for a new indication for DARZALEX Faspro®, which is co-formulated with Halozyme's ENHANZE® drug delivery technology.
This approval designates DARZALEX Faspro® as the first and only approved treatment for high-risk smoldering multiple myeloma (HR-SMM) in adult patients.
The new indication expands the therapeutic applications for DARZALEX Faspro with ENHANZE, reinforcing its role as a cornerstone therapy across all stages of multiple myeloma.

Nov 7, 2025, 1:30 PM

Press Release

Halozyme Therapeutics, Inc. Announces Pricing of Convertible Senior Notes Offering

HALO

Debt Issuance

New Projects/Investments

Halozyme Therapeutics, Inc. priced a private offering of $650.0 million aggregate principal amount of 0% convertible senior notes due 2031 and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032 on November 6, 2025.
The company granted initial purchasers a 13-day option to buy an additional $100.0 million of each series of notes.
The initial conversion price for both series is approximately $87.20 per share, representing a 27.5% premium over the common stock's closing price of $68.39 per share on November 6, 2025.
Halozyme expects to receive approximately $1.274 billion in net proceeds, which it plans to use primarily to repurchase existing 2027 and 2028 convertible senior notes (~$1.020 billion) and fund capped call transactions (~$182.7 million), with the remainder for general corporate purposes.

Nov 7, 2025, 1:02 PM

8-K

Halozyme Therapeutics Announces Proposed Offering of Convertible Senior Notes and Credit Agreement Amendment

HALO

Debt Issuance

Halozyme Therapeutics, Inc. announced a proposed offering of $650 million aggregate principal amount of convertible senior notes due 2031 and $650 million aggregate principal amount of convertible senior notes due 2032.
The company expects to grant initial purchasers an option to buy up to an additional $100 million of each series of notes.
Proceeds from the offering are intended to fund capped call transactions, repurchase outstanding 2027 and 2028 convertible senior notes, and for general corporate purposes.
On November 5, 2025, Halozyme also amended its Credit Agreement, increasing the aggregate commitments under its revolving credit facility to $750,000,000 with a new maturity date of November 5, 2030.
As of November 5, 2025, the company had $0 of outstanding borrowings under the Credit Agreement after giving effect to the amendment.

Nov 5, 2025, 9:59 PM

8-K

Halozyme Therapeutics Announces Proposed Offering of Convertible Senior Notes

HALO

Debt Issuance

New Projects/Investments

Halozyme Therapeutics, Inc. intends to offer $650 million aggregate principal amount of convertible senior notes due 2031 and $650 million aggregate principal amount of convertible senior notes due 2032.
The company expects to grant an option to initial purchasers to buy up to an additional $100 million aggregate principal amount of each series of notes.
The 2031 Notes will mature on February 15, 2031, and the 2032 Notes will mature on November 15, 2032.
A portion of the net proceeds will be used to fund capped call transactions and to repurchase outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028.
The remaining net proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions, and strategic transactions.

Nov 5, 2025, 9:05 PM

Press Release

Halozyme Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Announces Electrovive Acquisition

HALO

Earnings

Guidance Update

M&A

CFO Change

Halozyme reported strong Q3 2025 financial results, with royalty revenue increasing 52% year-over-year to $236 million and total revenue growing 22% to $354 million. Driven by this performance, the company raised its full-year 2025 guidance, now projecting total revenue of $1.3 billion-$1.375 billion and non-GAAP diluted EPS of $6.10-$6.50.
Key product developments include European Commission approval for Darzalex Subcutaneous in smoldering multiple myeloma , a 96% year-over-year increase in Vyvgart Hytrulo sales to $1.13 billion in Q3 , and Fesgo's nine-month revenue reaching CHF 1.8 billion (approximately $2.3 billion), up 54% year-over-year.
The company announced the acquisition of Electrovive to expand its drug delivery technology portfolio and repurchased $342 million of shares year-to-date. Additionally, the CFO will transition to a new opportunity in 2026 or by March 30, 2026.

Nov 3, 2025, 9:30 PM

Transcript

Halozyme Therapeutics Reports Record Q3 2025 Results and Raises Full-Year Guidance

HALO

Earnings

Guidance Update

M&A

Halozyme Therapeutics reported record Q3 2025 royalty revenue of $236 million, a 52% increase year-over-year, contributing to a total revenue of $354 million, up 22% year-over-year. Adjusted EBITDA for the quarter grew 35% to $248 million.
The company raised its full-year 2025 guidance, now projecting total revenue between $1.3 billion-$1.375 billion (representing 28%-35% growth over 2024) and royalty revenue of $850 million-$880 million (49%-54% growth). Non-GAAP diluted EPS is expected to be $6.10-$6.50.
This growth was primarily driven by the continued strong performance of its three established blockbuster subcutaneous therapies: Darzalex Subcutaneous, Phesgo, and VYVGART Hytrulo, with VYVGART Hytrulo projected to be the largest royalty dollar growth driver.
Halozyme announced the acquisition of Elektrofi, aiming to expand its drug delivery technology portfolio with Hypercon technology, which is expected to result in approximately 2x net debt-to-EBITDA at closing.
CFO Nicole LaBrosse will be transitioning from her role by March 30, 2026.

Nov 3, 2025, 9:30 PM

Transcript

Halozyme Therapeutics Reports Strong Q3 2025 Results and Raises Full-Year Guidance

HALO

Earnings

Guidance Update

Share Buyback

Halozyme Therapeutics reported strong Q3 2025 financial results, with Total Revenue of $354.3 million (up 22% from Q3 2024) and Adjusted EBITDA of $248.2 million (up 35%). Royalty Revenue increased 52% to $236.0 million.
The company raised its 2025 financial guidance, now projecting Total Revenue between $1,300 million and $1,375 million, Royalty Revenue between $850 million and $880 million, Adjusted EBITDA between $885 million and $935 million, and Non-GAAP Diluted EPS between $6.10 and $6.50.
Growth was driven by established blockbuster subcutaneous therapies and 13 recent ENHANZE® growth catalysts, including new indication and product approvals in Q3 2025.
Halozyme has completed $342 million in share repurchases year-to-date 2025 and plans for $500 million in repurchases for the full year 2025, contributing to a 10% reduction in diluted weighted average shares outstanding from 2019 to 2024.
The company is expanding its drug delivery technology portfolio with the potential acquisition of Elektrofi, Inc., introducing the Hypercon™ technology for ultra-concentrated biologic formulations.

Nov 3, 2025, 9:30 PM

Presentation

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for HALO.

No recent filings or transcripts found for HALO.